Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.

Carbone A, Botti G, Gloghini A, Simone G, Truini M, Curcio MP, Gasparini P, Mangia A, Perin T, Salvi S, Testi A, Verderio P.

J Mol Diagn. 2008 Nov;10(6):527-36. doi: 10.2353/jmoldx.2008.080052. Epub 2008 Oct 2.

3.

Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.

Papouchado BG, Myles J, Lloyd RV, Stoler M, Oliveira AM, Downs-Kelly E, Morey A, Bilous M, Nagle R, Prescott N, Wang L, Dragovich L, McElhinny A, Garcia CF, Ranger-Moore J, Free H, Powell W, Loftus M, Pettay J, Gaire F, Roberts C, Dietel M, Roche P, Grogan T, Tubbs R.

Am J Surg Pathol. 2010 Jun;34(6):767-76. doi: 10.1097/PAS.0b013e3181d96231.

PMID:
20421783
4.
5.

Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer.

Koh YW, Lee HJ, Lee JW, Kang J, Gong G.

Mod Pathol. 2011 Jun;24(6):794-800. doi: 10.1038/modpathol.2011.9. Epub 2011 Feb 11.

6.

Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.

Lim SJ, Cantillep A, Carpenter PM.

Hum Pathol. 2013 Nov;44(11):2590-6. doi: 10.1016/j.humpath.2013.07.005. Epub 2013 Sep 25.

PMID:
24075600
7.

Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.

Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B.

Histopathology. 2009 Jan;54(2):248-53. doi: 10.1111/j.1365-2559.2008.03185.x.

PMID:
19207950
8.

Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).

Fritzsche FR, Bode PK, Moch H, Kristiansen G, Varga Z, Bode B.

Am J Surg Pathol. 2010 Aug;34(8):1180-5. doi: 10.1097/PAS.0b013e3181e70e15.

9.

Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study.

Lee Y, Ryu Y, Jeong H, Chang H, Kim Y, Kim A.

Arch Med Res. 2012 Feb;43(2):139-44. doi: 10.1016/j.arcmed.2012.03.010. Epub 2012 Apr 1.

PMID:
22475781
10.

Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH).

Arnould L, Roger P, Macgrogan G, Chenard MP, Balaton A, Beauclair S, Penault-Llorca F.

Mod Pathol. 2012 May;25(5):675-82. doi: 10.1038/modpathol.2011.201. Epub 2012 Jan 6.

11.

Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach.

Dekker TJ, Borg ST, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ.

Breast Cancer Res. 2012 Jun 13;14(3):R93.

13.

Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma.

Ramieri MT, Murari R, Botti C, Pica E, Zotti G, Alo PL.

Anticancer Res. 2010 Apr;30(4):1287-92.

PMID:
20530441
14.

Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH.

Bartlett JM, Campbell FM, Ibrahim M, Wencyk P, Ellis I, Kay E, Connolly Y, O'Grady A, Di Palma S, Starczynski J, Morgan JM, Jasani B, Miller K.

Am J Clin Pathol. 2009 Oct;132(4):514-20. doi: 10.1309/AJCPXY3MJ6GSRCYP.

PMID:
19762528
15.

Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.

Bilous M, Morey AL, Armes JE, Bell R, Button PH, Cummings MC, Fox SB, Francis GD, Waite B, McCue G, Raymond WA, Robbins PD, Farshid G.

Breast Cancer Res Treat. 2012 Jul;134(2):617-24. doi: 10.1007/s10549-012-2093-6. Epub 2012 Jun 8.

16.

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.

Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B.

Hum Pathol. 2010 Jan;41(1):103-6. doi: 10.1016/j.humpath.2009.07.001. Epub 2009 Sep 16.

PMID:
19762065
17.

HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).

Boers JE, Meeuwissen H, Methorst N.

Histopathology. 2011 Feb;58(3):383-94. doi: 10.1111/j.1365-2559.2011.03760.x. Epub 2011 Feb 16.

18.

Emerging technologies for assessing HER2 amplification.

Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J, van de Vijver M.

Am J Clin Pathol. 2009 Oct;132(4):539-48. doi: 10.1309/AJCPV2I0HGPMGBSQ. Review.

PMID:
19762531
19.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2007 Jan 1;25(1):118-45. Epub 2006 Dec 11.

PMID:
17159189
20.

Supplemental Content

Support Center